Sugi Predict

Sugi Predict / Compounds / SCHEMBL467321

SCHEMBL467321

SCHEMBL467321

Fc1ccc(C[Mg]Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 3/20 0.48
▸ IDO1 P14902 4/20 0.46
▸ LOXL2 Q9Y4K0 1/20 0.46
▸ MAOB P27338 1/20 0.41
▸ AGXT P21549 2/20 0.41
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ PLA2G1B P04054 1/20 0.37
▸ ATG4B Q9Y4P1 1/20 0.37
▸ MIF P14174 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ CYP19A1 P11511 1/20 0.36
▸ CYP11B1 P15538 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36
▸ AOC3 Q16853 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1003726 0.97 TAAR1 (0.46) TAAR1IDO1LOXL2MAOBAGXT
SCHEMBL1141849 0.76 TAAR1 (0.50) TAAR1IDO1MAOBAGXTLMNA
SCHEMBL31453506 0.75 TAAR1 (0.56) TAAR1IDO1LOXL2MAOBAGXT
SCHEMBL14484673 0.74 IDO1 (0.41) TAAR1IDO1
SCHEMBL558967 0.74 TAAR1 (0.48) TAAR1IDO1LMNA
SCHEMBL452138 0.74 IDO1 (0.46) TAAR1IDO1LOXL2MAOBAGXT
SCHEMBL560202 0.74 CYP1A2 (0.48) TAAR1IDO1AGXTLMNACYP19A1
SCHEMBL1003357 0.72 TAAR1 (0.55) TAAR1IDO1MAOBAGXTNPC1
Hydrochloric Acid SCHEMBL4774333 0.70 CALM1 (0.43) TAAR1IDO1LOXL2MAOBAGXT
SCHEMBL28673849 0.70 CALM1 (0.43) TAAR1IDO1LOXL2MAOBCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025242747-A1 MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS MERCK PATENT GMBH (DE) 2025-11-27 — — WO claimed
US-7273948-B2 Process of preparing esters and ethers of probucol and derivatives thereof ATHEROGENICS, INC. (US) 2007-09-25 — — US claimed
EP-1594824-A4 PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF ATHEROGENICS INC (US) 2007-04-04 — — EP claimed
EP-1639043-A2 CURABLE FLAME RETARDANT EPOXY RESIN COMPOSITIONS DOW GLOBAL TECHNOLOGIES INC. (US) 2006-03-29 — — EP claimed
EP-1594824-A2 PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF Atherogenics, Inc. (US) 2005-11-16 — — EP claimed
WO-2004108826-A2 CURABLE FLAME RETARDANT EPOXY RESIN COMPOSITIONS DOW GLOBAL TECHNOLOGIES INC. (US) 2004-12-16 — — WO claimed
US-20040204485-A1 Process of preparing esters and ethers of probucol and derivatives thereof CRABTREE ACQUISITION CO, LLC 2004-10-14 — — US claimed
WO-2004062622-A2 PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF ATHEROGENICS, INC. (US) 2004-07-29 — — WO claimed
WO-2025242747-A1 MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS MERCK PATENT GMBH (DE) 2025-11-27 — — WO disclosed
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS LLC (US) 2025-10-23 — — US disclosed
US-12312359-B2 Inhibitors of the menin-MLL interaction VITAE PHARMACEUTICALS, LLC (US) 2025-05-27 — — US disclosed
WO-2025067168-A1 AZA FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 苏州爱科百发生物医药技术有限公司 2025-04-03 — — WO disclosed
US-20250074909-A1 AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2025-03-06 — — US disclosed
US-12157733-B2 Aminotriazolopyridines as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-12-03 — — US disclosed
EP-0104549-A2 Azolyl butanoles BAYER AG (DE) 1984-04-04 — — EP disclosed
US-4071570-A ANTIARRHYTHMIC AGENTS MERCK & CO., INC. (US) 1978-01-31 — — US disclosed
US-4070360-A ANALGESICS MERCK & CO., INC. (US) 1978-01-24 — — US disclosed
US-4070359-A ISOMERIZATION, CYCLIZATION, ANALGESICS MERCK & CO., INC. (US) 1978-01-24 — — US disclosed
US-4033968-A ANALGESICS MERCK & CO., INC. (US) 1977-07-05 — — US disclosed
US-3978127-A ANTIARRHYTHMIC MERCK & CO., INC. (US) 1976-08-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074909-A1 AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS RIPK1, RIPK3, RIPK4 TAAR1 1549/4885IDO1 886/4885LOXL2 2790/4885
US-12312359-B2 Inhibitors of the menin-MLL interaction MLLT1, MEN1, MLLT3 TAAR1 4582/4885IDO1 3582/4885LOXL2 3164/4885
US-12157733-B2 Aminotriazolopyridines as kinase inhibitors RIPK1, RIPK3, RIPK4 TAAR1 1549/4885IDO1 886/4885LOXL2 2790/4885
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION MLLT1, MEN1, MLLT3 TAAR1 4582/4885IDO1 3582/4885LOXL2 3164/4885
US-20040204485-A1 Process of preparing esters and ethers of probucol and derivatives thereof NR3C2, MGLL, GCG TAAR1 3193/4885IDO1 4697/4885LOXL2 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.